India's Strides Buys Into Generics

Fast-expanding Indian generic drugmaker Strides Arcolab is to acquire Singapore's leading manufacturer of off-patent medicines, Drug Houses of Australia (DHA). The value of deal - which will see local conglomerate Haw Par exit the generics sector - is valued at US$19.7mn. DHA operates a manufacturing unit in Jurong, and also markets its products in Malaysia, Hong Kong and

To read the full article, please take a trial.